IN2014CH00390A - - Google Patents

Download PDF

Info

Publication number
IN2014CH00390A
IN2014CH00390A IN390CH2014A IN2014CH00390A IN 2014CH00390 A IN2014CH00390 A IN 2014CH00390A IN 390CH2014 A IN390CH2014 A IN 390CH2014A IN 2014CH00390 A IN2014CH00390 A IN 2014CH00390A
Authority
IN
India
Prior art keywords
neu
peptide
her2
cellular immunity
provides
Prior art date
Application number
Inventor
Katsuyuki Okubo
Yoshiki Maeda
takuya Shishido
Daisuke Asari
Arimichi Okazaki
Kyohei Matsushita
Wenjing Li
Mitsuhiko Hori
Haruo Sugiyama
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of IN2014CH00390A publication Critical patent/IN2014CH00390A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Abstract

The invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity comprising (i) HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter.
IN390CH2014 2013-02-05 2014-01-29 IN2014CH00390A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013020799 2013-02-05

Publications (1)

Publication Number Publication Date
IN2014CH00390A true IN2014CH00390A (en) 2015-07-31

Family

ID=50028736

Family Applications (1)

Application Number Title Priority Date Filing Date
IN390CH2014 IN2014CH00390A (en) 2013-02-05 2014-01-29

Country Status (8)

Country Link
US (1) US20140220100A1 (en)
EP (1) EP2762158A1 (en)
JP (1) JP2014169278A (en)
KR (1) KR20140100415A (en)
CN (1) CN103961696A (en)
CA (1) CA2840997A1 (en)
IN (1) IN2014CH00390A (en)
RU (1) RU2014102938A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103961307B (en) 2013-02-05 2019-11-29 日东电工株式会社 For percutaneous administration of with WT1 peptide cancer vaccine composition
US10195258B2 (en) 2013-02-05 2019-02-05 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
TW201618790A (en) * 2014-10-02 2016-06-01 Nitto Denko Corp Vaccine pharmaceutical composition for transdermal administration
BR112022007369A2 (en) * 2019-10-24 2022-07-05 Lts Lohmann Therapie Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF FINGOLIMODE

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU2002252378B2 (en) * 2001-03-19 2007-10-18 Intercell Usa, Inc. Transcutaneous immunostimulation
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
WO2005087238A2 (en) 2004-03-15 2005-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
DE102004049223A1 (en) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Preparation for vaccination, vaccination and use of a vaccine preparation
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
JP2009544291A (en) * 2006-07-25 2009-12-17 フォージー ヴァクシンズ ピーティーワイ エルーティーディー Mucin 1 (MUC1) T cell epitope-derived peptide-containing cancer vaccine
US20080112974A1 (en) 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
US8222214B2 (en) * 2007-06-01 2012-07-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
EP2413964B1 (en) * 2009-04-01 2019-11-13 University of Miami Vaccine compositions and methods of use thereof
CN102475886A (en) * 2010-11-29 2012-05-30 南开大学 Novel anti-breast cancer polypeptide vaccine

Also Published As

Publication number Publication date
EP2762158A1 (en) 2014-08-06
CA2840997A1 (en) 2014-08-05
CN103961696A (en) 2014-08-06
KR20140100415A (en) 2014-08-14
RU2014102938A (en) 2015-08-10
JP2014169278A (en) 2014-09-18
US20140220100A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
MX2022004374A (en) Treatment of cancer using tlr9 agonist with checkpoint inhibitors.
IN2014CH00396A (en)
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
IN2014CH00391A (en)
PH12016501411A1 (en) Bifunctional cytotoxic agents
CL2015002472A1 (en) As inhibitors of mutant idh-yl-oxazolidin-2-ones 3-pyrimidin-4.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
MX371187B (en) Therapeutic peptides.
CL2015002628A1 (en) Heteroaryl compounds and their uses.
MX2016004570A (en) Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy.
CY1117214T1 (en) COMPOSITION FOR CONTROLLED OVENTION STUDY
MX2015011899A (en) Methods of treating cancer and preventing cancer drug resistance.
MX2017007595A (en) Immunotherapy for angiogenic disease.
IN2014CH00393A (en)
IN2014CH00395A (en)
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MY191539A (en) Streptococcal vaccine
MX2018006249A (en) Novel anti-emr2 antibodies and methods of use.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MX2016005285A (en) Conjugates of somatostatin and its analogs.
IN2014CH00386A (en)
IN2014CH00390A (en)
MX2018007817A (en) Novel anti-mmp16 antibodies and methods of use.